Biotechnology

YZYBIO-B

Youzhiyou Biology: M701 Clinical Trial Results to be Presented at 2026 ASCO Annual Meeting

YZYBIO-B released FY2025 Q3 earnings on March 27, 2026 (BJT) with actual revenue of HKD 12.29 M and actual EPS of HKD -0.073

YZYBIO-B released FY2025 9 Months earnings on March 27 BJT, actual revenue HKD 60.33 M, actual EPS HKD -0.4016

YZYBIO-B released FY2025 Q4 earnings on March 27 During-Market (BJT), actual revenue HKD 12.5 M, actual EPS HKD -0.0742

YZYBIO-B released FY2025 earnings on March 27 During-Market (BJT), actual revenue HKD 73.07 M, actual EPS HKD -0.4777

YZYBIO-B FY2025 Annual Earnings Release on March 27, 2026 During-Market BJT

Yuzychou Bio-B Releases Mid-Term Data of Phase II Clinical Trial for M701 Drug

YZYBIO-B released FY2025 Q1 earnings on August 26 (BJT), actual revenue HKD 23.76 M, actual EPS HKD -0.1625

YZYBIO-B released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue HKD 24.28 M, actual EPS HKD -0.166

YZYBIO-B released FY2025 Semi-Annual Earnings on August 26 During-Market BJT, actual revenue HKD 48.04 M, actual EPS HKD -0.3286

YZYBIO-B to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Youzhiyou Biologics-B Grants 3.55 Million Share Options

YZYBIO-B released FY2024 9 Months earnings on March 28, 2025 (BJT), actual revenue HKD 61.24 M, actual EPS HKD -0.4913

YZYBIO-B released FY2024 Q3 earnings on March 28, 2025 (BJT), with actual revenue of HKD 58.18 M and EPS of HKD -0.0549

YZYBIO-B released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue HKD 55.84 M, actual EPS HKD -0.0526

YZYBIO-B released FY2024 Annual Earnings on March 28 After-Market (BJT), actual revenue HKD 116.7 M, actual EPS HKD -0.545

Youzhiyou Biotechnology-B Expects Comprehensive Losses to Decrease by at Least 35% in 2024

YZYBIO-B to Release FY2024 Earnings on March 28 After-Market BJT

Zhengda Tianqing Signs Exclusive Licensing and Cooperation Agreement with Youzhiyou Biopharmaceutical

Zhengda Tianqing Signs Exclusive License and Collaboration Agreement for M701 with Youzhiyou Biopharmaceutical

SINOFORTUNE FIN

PAN ASIA DATA H

HUASHENG INTL

IMAGI INT'L

SUPERLAND GROUP

QIANHAI HEALTH

STELUX HOLDINGS

JOLIMARK

CASSAVA RES

I-CABLE COMM

02496

YZYBIO-B announced its full-year results for the year ended December last year, with a revenue of RMB 66.858 million, a year-on-year decrease of 38%. The loss narrowed to RMB 84.732 million, compared to a loss of RMB 97.599 million in the same period last year; the loss per share was RMB 0.44. No dividend was declared

AASTOCKS

"Performance" YZYBIO's annual loss narrowed to RMB 84.732 million

Wuhan YZY Biopharma (SEHK:2496) reported a revenue of C¥44.4 million and a basic EPS loss of C¥0.30 for 1H 2025, with a net loss of C¥58.8 million. Despite a revenue increase from C¥2.8 million in 1H 2024, the company continues to face significant losses. The current P/S ratio of 4.7x is below industry averages, indicating market skepticism about its profitability. While some investors see potential in the narrowing loss trend, concerns about negative equity and share price volatility persist, highlighting the risks involved in the company's financial outlook.

Simplywall

Wuhan YZY Biopharma (SEHK:2496) Loss Deepens In 1H 2025 Challenging Improving Loss Trend Narrative

YZYBIO-B fell 12.28%; Kangfang Biotech rose 1.03%, with a transaction volume of HKD 785 million; Sanofi Biotech rose 4.28%, with a transaction volume of HKD 753 million; Innovent Biologics rose 0.06%, with a transaction volume of HKD 749 million; BeiGene fell 0.57%, with a market capitalization of HKD 267.9 billion

HK Stock Alerts

Hong Kong Stock Movement: YZYBIO-B fell by 12.28%, with clear capital flow and increased volatility attracting market attention

Wuhan YZY Biopharma Co., Ltd. has received FDA approval for its Investigational New Drug application for M701, a bispecific antibody targeting EpCAM and CD3. This approval allows for a phase Ib/II clinical trial in the U.S. for patients with malignant pleural effusion from advanced epithelial tumors. The company aims to address significant unmet medical needs in oncology. The latest analyst rating for the stock (HK:2496) is a Hold with a price target of HK$8.00, and the current market cap is HK$1.53B.

Tip Ranks

Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion

YZYBIO-B announced the transfer of an unused industrial building located in the east of Wuhan City, Hubei Province, with a land area of approximately 25,533 square meters, to Wuhan Yiruid. The cash consideration is RMB 36.88 million

YZYBIO is selling industrial land in Wuhan for RMB 36.88 million

YZYBIO-B announced that the clinical trial application for the biosimilar drug Y225 has been approved by the National Medical Products Administration of China. Y225 is a bispecific antibody biosimilar used for the treatment of Hemophilia A, specifically the drug Shuyou Lile (Aimeisai Zhu Dan Zhi Ye, anti-FIX and FX)

YZYBIO's biosimilar Y225 clinical trial application approved

YZYBIO-B announced that the mid-term data of its bispecific antibody M701 in the Phase II clinical study for the treatment of malignant pleural effusion caused by advanced non-small cell lung cancer has been presented at the 2025 European Society for Medical Oncology (ESMO). The study is a randomized, controlled, multicenter, open-label trial, with the primary endpoint being puncture-free survival time, and secondary endpoints including the objective response rate of malignant pleural effusion. As of March 7, 2025, a total of 54 patients participated, with 26 in the experimental group and 28 in the control group

Zhitong

YZYBIO-B: Mid-term data from the Phase II study of M701 for malignant pleural effusion will be announced at the 2025 ESMO conference

YZYBIO-B(02496.HK)